On September 11, Ge Longhui Pharmaceutical (002826.SZ) announced that TAPI Healthcare Inc. (hereinafter referred to as “TAPI”), a second-tier wholly-owned subsidiary of the company, plans to make targeted capital cuts to the participating company Pier 88 Health Limited (hereinafter referred to as “Cayman Piers”). The two parties intend to sign a “Share Repurchase Agreement”. The agreement agreed that TAPI intends to sell all of its shares, with a total repurchase price of US$6,491,178.08.
易明医药(002826.SZ)：二级全资子公司拟对开曼彼爱进行定向减资
Tibet AIM Pharm. Inc. (002826.SZ): The second-level wholly-owned subsidiary plans to conduct targeted capital reduction for Cayman Biai.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated